



GP 1643

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

P#5

Applicants: Gary A. Bannon, A. Wesley Burks, Jr., Hugh A. Sampson, Howard B. Sosin, Nina E. King, Soheila J. Maleki, Cathie Connaughton, Randall A. Kopper, Patrick A. Rabjohn, David S. Shin, and Cesar M. Compadre

RECEIVED

Serial No.: 09/494,096

Art Unit: 1643

FEB 15 2001

Filed: January 28, 2000

Examiner: Not Yet Assigned

TECH CENTER 1600/2900

For: *METHODS AND REAGENTS FOR DECREASING ALLERGIC REACTIONS*

Assistant Commissioner for Patents  
Washington, D.C. 20231

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449, copies of the documents cited therein, and a copy of the International Search Report, mailed 11 October 2000, in the corresponding PCT application PCT/US00/05487.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 01-2507.

## Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 95/07933 A1	03-23-1995	Allergene, Inc.	PCT
WO 97/24139 A1	07-10-1997	University of Arkansas	PCT
WO 98/43657 A2	10-08-1998	Merck Patent GMBH	PCT

U.S.S.N.: 09/494,096  
Filed: January 28, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

WO 99/38978 A1 08-05-1999

University of Arkansas; PCT  
Mt. Sinai School of Medicine  
of the City of New York

### Publications

FERREIRA, et al., "Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy," *FASEB J* 12:231-242 (1998).

RABJOHN, et al., "Molecular cloning and epitope analysis of the peanut allergen Ara h 3," *Journal of Clinical Investigation* 103(4):535-541 (1999).

TAKAI, et al., "Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy," *Nature Biotechnology* 15:754-58 (1997).


TAKASHI, et al., "Engineering of hypoallergenic mutants of the *Brassica* pollen allergen, Bra r 1, for immunotherapy," *FEBS Letters* 434:255-260 (1998).

U.S.S.N.: 09/494,096  
Filed: January 28, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

**Remarks**

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



\_\_\_\_\_  
Patrea L. Pabst  
Reg. No. 31,284

Dated: February 6, 2001

ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 W. Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8794  
(404) 873-8795 (fax)

U.S.S.N.: 09/494,096  
Filed: January 28, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT



RECEIVED

FEB 15 2001

TECH CENTER 1600/2900

**Certificate of Mailing under 37 CFR §1.8(a)**

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: February 6, 2001

  
Kimberly L. Adams